{"id":63022,"date":"2026-04-13T20:26:57","date_gmt":"2026-04-13T12:26:57","guid":{"rendered":"https:\/\/flcube.com\/?p=63022"},"modified":"2026-04-13T20:26:58","modified_gmt":"2026-04-13T12:26:58","slug":"cansino-biologics-secures-nmpa-approval-for-pankangxin-chinas-first-three-component-acellular-dtap-vaccine","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63022","title":{"rendered":"CanSino Biologics Secures NMPA Approval for Pankangxin, China&#8217;s First Three-Component Acellular DTaP Vaccine"},"content":{"rendered":"\n<p><strong>CanSino Biologics Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6185:HKG\">HKG: 6185<\/a>) has announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has granted market approval for <strong>Pankangxin<\/strong>, its acellular diphtheria-tetanus-pertussis (<strong>DTaP<\/strong>) combined vaccine for infants. This marks the first approval of a three-component acellular pertussis vaccine in China, offering enhanced protection and a superior safety profile compared to existing options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-differentiation\">Product Profile &amp; Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Vaccine Name<\/strong><\/td><td>Pankangxin (Infant DTaP)<\/td><\/tr><tr><td><strong>Antigens<\/strong><\/td><td>PT (Pertussis Toxin), FHA (Filamentous Hemagglutinin), <strong>PRN (Pertactin)<\/strong><\/td><\/tr><tr><td><strong>Key Innovation<\/strong><\/td><td>First 3-component acellular DTaP approved in China; includes critical PRN antigen<\/td><\/tr><tr><td><strong>Safety Advantages<\/strong><\/td><td><strong>No thimerosal, no antibiotics, no animal-derived components<\/strong><\/td><\/tr><tr><td><strong>Tolerability<\/strong><\/td><td>&gt;50% reduction in post-booster fever incidence vs. control<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence\">Clinical Evidence<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enhanced Immunogenicity:<\/strong> A large-scale Phase III clinical trial demonstrated that Pankangxin induces a <strong>more potent immune response<\/strong>. It achieved <strong>superior efficacy<\/strong> in primary immunization against Pertussis Toxin (PT) compared to the control group.<\/li>\n\n\n\n<li><strong>Comprehensive Protection:<\/strong> The inclusion of the <strong>PRN (pertactin)<\/strong> antigen, in addition to PT and FHA, provides a broader immune response against <em>Bordetella pertussis<\/em>, the bacterium that causes whooping cough, potentially leading to more durable and effective protection.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-amp-market-impact\">Strategic &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Filling a Critical Gap:<\/strong> Pankangxin addresses a significant unmet need in China\u2019s national immunization program by providing a modern, acellular alternative with a full complement of pertussis antigens, aligning with global best practices.<\/li>\n\n\n\n<li><strong>Safety as a Key Driver:<\/strong> The vaccine\u2019s clean formulation\u2014free of common excipients like thimerosal and antibiotics\u2014and its markedly improved tolerability profile (notably the >50% lower fever rate) are expected to be major drivers for adoption by parents and healthcare providers.<\/li>\n\n\n\n<li><strong>Market Leadership:<\/strong> As the first mover with this advanced formulation, CanSino is positioned to capture a substantial share of the large and essential Chinese pediatric vaccine market, strengthening its position beyond its well-known COVID-19 vaccine portfolio.<\/li>\n\n\n\n<li><strong>Public Health Impact:<\/strong> The introduction of a more effective and better-tolerated DTaP vaccine has the potential to significantly improve pertussis control and reduce disease burden among Chinese infants.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief reports on a marketing approval from the NMPA. Commercial success is subject to inclusion in national or provincial immunization programs, manufacturing scale-up, and market acceptance. There can be no assurance of future sales volume or revenue.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CanSino Biologics Inc. (HKG: 6185) has announced that China\u2019s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63024,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[466,884,15,12],"class_list":["post-63022","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cansino-biologics","tag-hkg-6185","tag-product-approvals","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CanSino Biologics Secures NMPA Approval for Pankangxin, China&#039;s First Three-Component Acellular DTaP Vaccine - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CanSino Biologics Inc. (HKG: 6185) has announced that China\u2019s National Medical Products Administration (NMPA) has granted market approval for Pankangxin, its acellular diphtheria-tetanus-pertussis (DTaP) combined vaccine for infants. This marks the first approval of a three-component acellular pertussis vaccine in China, offering enhanced protection and a superior safety profile compared to existing options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63022\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CanSino Biologics Secures NMPA Approval for Pankangxin, China&#039;s First Three-Component Acellular DTaP Vaccine\" \/>\n<meta property=\"og:description\" content=\"CanSino Biologics Inc. (HKG: 6185) has announced that China\u2019s National Medical Products Administration (NMPA) has granted market approval for Pankangxin, its acellular diphtheria-tetanus-pertussis (DTaP) combined vaccine for infants. This marks the first approval of a three-component acellular pertussis vaccine in China, offering enhanced protection and a superior safety profile compared to existing options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63022\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T12:26:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T12:26:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1304.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63022#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63022\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CanSino Biologics Secures NMPA Approval for Pankangxin, China&#8217;s First Three-Component Acellular DTaP Vaccine\",\"datePublished\":\"2026-04-13T12:26:57+00:00\",\"dateModified\":\"2026-04-13T12:26:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63022\"},\"wordCount\":378,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63022#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1304.webp\",\"keywords\":[\"CanSino Biologics\",\"HKG: 6185\",\"Product approvals\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63022#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63022\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63022\",\"name\":\"CanSino Biologics Secures NMPA Approval for Pankangxin, China's First Three-Component Acellular DTaP Vaccine - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63022#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63022#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1304.webp\",\"datePublished\":\"2026-04-13T12:26:57+00:00\",\"dateModified\":\"2026-04-13T12:26:58+00:00\",\"description\":\"CanSino Biologics Inc. (HKG: 6185) has announced that China\u2019s National Medical Products Administration (NMPA) has granted market approval for Pankangxin, its acellular diphtheria-tetanus-pertussis (DTaP) combined vaccine for infants. This marks the first approval of a three-component acellular pertussis vaccine in China, offering enhanced protection and a superior safety profile compared to existing options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63022#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63022\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63022#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1304.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1304.webp\",\"width\":1080,\"height\":608,\"caption\":\"CanSino Biologics Secures NMPA Approval for Pankangxin, China's First Three-Component Acellular DTaP Vaccine\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63022#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CanSino Biologics Secures NMPA Approval for Pankangxin, China&#8217;s First Three-Component Acellular DTaP Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CanSino Biologics Secures NMPA Approval for Pankangxin, China's First Three-Component Acellular DTaP Vaccine - Insight, China&#039;s Pharmaceutical Industry","description":"CanSino Biologics Inc. (HKG: 6185) has announced that China\u2019s National Medical Products Administration (NMPA) has granted market approval for Pankangxin, its acellular diphtheria-tetanus-pertussis (DTaP) combined vaccine for infants. This marks the first approval of a three-component acellular pertussis vaccine in China, offering enhanced protection and a superior safety profile compared to existing options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63022","og_locale":"en_US","og_type":"article","og_title":"CanSino Biologics Secures NMPA Approval for Pankangxin, China's First Three-Component Acellular DTaP Vaccine","og_description":"CanSino Biologics Inc. (HKG: 6185) has announced that China\u2019s National Medical Products Administration (NMPA) has granted market approval for Pankangxin, its acellular diphtheria-tetanus-pertussis (DTaP) combined vaccine for infants. This marks the first approval of a three-component acellular pertussis vaccine in China, offering enhanced protection and a superior safety profile compared to existing options.","og_url":"https:\/\/flcube.com\/?p=63022","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-13T12:26:57+00:00","article_modified_time":"2026-04-13T12:26:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1304.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63022#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63022"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CanSino Biologics Secures NMPA Approval for Pankangxin, China&#8217;s First Three-Component Acellular DTaP Vaccine","datePublished":"2026-04-13T12:26:57+00:00","dateModified":"2026-04-13T12:26:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63022"},"wordCount":378,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63022#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1304.webp","keywords":["CanSino Biologics","HKG: 6185","Product approvals","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63022#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63022","url":"https:\/\/flcube.com\/?p=63022","name":"CanSino Biologics Secures NMPA Approval for Pankangxin, China's First Three-Component Acellular DTaP Vaccine - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63022#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63022#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1304.webp","datePublished":"2026-04-13T12:26:57+00:00","dateModified":"2026-04-13T12:26:58+00:00","description":"CanSino Biologics Inc. (HKG: 6185) has announced that China\u2019s National Medical Products Administration (NMPA) has granted market approval for Pankangxin, its acellular diphtheria-tetanus-pertussis (DTaP) combined vaccine for infants. This marks the first approval of a three-component acellular pertussis vaccine in China, offering enhanced protection and a superior safety profile compared to existing options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63022#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63022"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63022#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1304.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1304.webp","width":1080,"height":608,"caption":"CanSino Biologics Secures NMPA Approval for Pankangxin, China's First Three-Component Acellular DTaP Vaccine"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63022#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CanSino Biologics Secures NMPA Approval for Pankangxin, China&#8217;s First Three-Component Acellular DTaP Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1304.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63022"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63022\/revisions"}],"predecessor-version":[{"id":63025,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63022\/revisions\/63025"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63024"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}